Jain, Rajul K <br/><br/>
Novel phase I study combining G1 phase, S phase, and G2/M phase cell cycle inhibitors in patients with advanced malignancies.  [electronic resource] 

 -  Cell cycle (Georgetown, Tex.)  2015 
 - 3434-40 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article 
<br/><br/><label>ISSN: </label>1551-4005 
<br/><br/><label>Standard No.: </label>10.1080/15384101.2015.1090065  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Bortezomib--administration & dosage<br/>Computer Simulation<br/>Disease Progression<br/>Disease-Free Survival<br/>Drug Administration Schedule<br/>Female<br/>G1 Phase Cell Cycle Checkpoints--drug effects<br/>G2 Phase Cell Cycle Checkpoints--drug effects<br/>Humans<br/>Kaplan-Meier Estimate<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Models, Biological<br/>Molecular Targeted Therapy<br/>Neoplasms--drug therapy<br/>S Phase Cell Cycle Checkpoints--drug effects<br/>Sirolimus--administration & dosage<br/>Texas<br/>Time Factors<br/>Topotecan--administration & dosage<br/>Treatment Outcome<br/>Young Adult